Pharmaceutical latest report Short Bowel Syndrome - Pipeline Review, H1 2017 report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Short Bowel Syndrome Pipeline - Companies Involved in Therapeutics Development : Ardelyx Inc, Hanmi Pharmaceuticals Co Ltd, Naia Ltd, Nutrinia Ltd, OxThera AB, Sancilio & Company Inc, Shire Plc, Tasly Pharmaceutical Group Co Ltd, Zealand Pharma AS.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=1057938 .

Drug Profile: exenatide, glepaglutide, GXG-8, HM-15910, melatonin, NB-1002, NTRA-9620, Oxabact, RDX-98940, SC-403, teduglutide. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 1, 2 and 6 respectively.

Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1057938

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

Inquire more on this Research Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1057938

List of Tables
Number of Products under Development for Short Bowel Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Short Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2017
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Short Bowel Syndrome - Pipeline by Naia Ltd, H1 2017
Short Bowel Syndrome - Pipeline by Nutrinia Ltd, H1 2017
Short Bowel Syndrome - Pipeline by OxThera AB, H1 2017
Short Bowel Syndrome - Pipeline by Sancilio & Company Inc, H1 2017
Short Bowel Syndrome - Pipeline by Shire Plc, H1 2017
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H1 2017
Short Bowel Syndrome - Dormant Projects, H1 2017
Short Bowel Syndrome - Discontinued Products, H1 2017

About Us:
ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help in purchase decision by mapping your information needs with our huge collection of reports.